The FDA has issued a complete response letter rejecting Scholar Rock’s apitegromab, intended for spinal muscular atrophy (SMA), due to unresolved manufacturing problems at a contract facility owned by Novo Nordisk. The facility faced quality-control concerns including pest contamination. Scholar Rock plans to resubmit once the issues are addressed but has not provided a timeline, casting uncertainty on the drug’s approval and launch.